Clinical Trial of Brain-Penetrating HIV Drugs to Prevent Cognitive Impairment in China
Status:
Completed
Trial end date:
2015-07-01
Target enrollment:
Participant gender:
Summary
This primary aim of the project is to determine the association between antiretroviral
therapy that better distributes into the central nervous system and prevention of
HIV-associated neurocognitive impairment.
Phase:
Phase 4
Details
Lead Sponsor:
University of California, San Diego
Collaborators:
Beijing Ditan Hospital Beijing YouAn Hospital National Center for AIDS/STD Control and Prevention, China CDC National Institute of Mental Health (NIMH) Peking University
Treatments:
Efavirenz Lamivudine Lamivudine, zidovudine drug combination Nevirapine Tenofovir Zidovudine